{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:16:12Z","timestamp":1779336972471,"version":"3.51.4"},"reference-count":159,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Membrane transporters interact not only with endogenous substrates but are also engaged in the transport of xenobiotics, including drugs. While the coordinated function of uptake (solute carrier family\u2014SLC and SLCO) and efflux (ATP-binding cassette family\u2014ABC, multidrug and toxic compound extrusion family\u2014MATE) transporter system allows vectorial drug transport, efflux carriers alone achieve barrier functions. The modulation of transport functions was proved to be effective in the treatment strategies of various pathological states. Sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors are the drugs most widely applied in clinical practice, especially in the treatment of diabetes mellitus and heart failure. Sodium taurocholate co-transporting polypeptide (NTCP) serves as virus particles (HBV\/HDV) carrier, and inhibition of its function is applied in the treatment of hepatitis B and hepatitis D by myrcludex B. Inherited cholestatic diseases, such as Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) can be treated by odevixibat and maralixibat, which inhibit activity of apical sodium-dependent bile salt transporter (ASBT). Probenecid can be considered to increase uric acid excretion in the urine mainly via the inhibition of urate transporter 1 (URAT1), and due to pharmacokinetic interactions involving organic anion transporters 1 and 3 (OAT1 and OAT3), it modifies renal excretion of penicillins or ciprofloxacin as well as nephrotoxicity of cidofovir. This review discusses clinically approved drugs that affect membrane\/drug transporter function.<\/jats:p>","DOI":"10.3390\/ijms25136926","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:19:26Z","timestamp":1719461966000},"page":"6926","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Transporter Proteins as Therapeutic Drug Targets\u2014With a Focus on SGLT2 Inhibitors"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3162-4870","authenticated-orcid":false,"given":"Nina","family":"Komaniecka","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Maroszek","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Drozdzik","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Oswald","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-7168","authenticated-orcid":false,"given":"Marek","family":"Drozdzik","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s43440-020-00139-6","article-title":"Intestinal Drug Transporters in Pathological States: An Overview","volume":"72","author":"Drozdzik","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s13238-015-0148-2","article-title":"The Physiological Role of Drug Transporters","volume":"6","author":"Liang","year":"2015","journal-title":"Protein Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02977789","article-title":"Induction of Phase I, II and III Drug Metabolism\/Transport by Xenobiotics","volume":"28","author":"Xu","year":"2005","journal-title":"Arch. Pharm. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","article-title":"Multidrug Resistance Mediated by the Breast Cancer Resistance Protein BCRP (ABCG2)","volume":"22","author":"Ross","year":"2003","journal-title":"Oncogene"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105096","DOI":"10.1016\/j.isci.2022.105096","article-title":"A Structure and Evolutionary-Based Classification of Solute Carriers","volume":"25","author":"Ferrada","year":"2022","journal-title":"iScience"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"You, G., Morris, M.E., and Binghe, W. (2007). Overview of Drug Transporter Families. Drug Transporters: Molecular Characterization and Role in Drug Disposition, John Wiley & Sons, Ltd.","DOI":"10.1002\/9780470140505"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cpt.1112","article-title":"Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance","volume":"104","author":"Taub","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yan, Q. (2010). Targeting Drug Transporters\u2013Combining in Silico and in Vitro Approaches to Predict in Vivo. Membrane Transporters in Drug Discovery and Development: Methods and Protocols, Humana Press. Methods in Molecular Biology.","DOI":"10.1007\/978-1-60761-700-6"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Napier, S., and Bingham, M. (2009). Membrane Transporters: Structure, Function and Targets for Drug Design. Transporters as Targets for Drugs, Springer. Topics in Medicinal Chemistry.","DOI":"10.1007\/978-3-540-87912-1"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1124\/pr.55.3.1","article-title":"Impact of Drug Transporter Studies on Drug Discovery and Development","volume":"55","author":"Mizuno","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 Inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and Safety of Canagliflozin Monotherapy in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise","volume":"15","author":"Cefalu","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin Monotherapy with Sitagliptin as an Active Comparator in Patients with Type 2 Diabetes: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12888","article-title":"Phase III, Efficacy and Safety Study of Ertugliflozin Monotherapy in People with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise Alone","volume":"19","author":"Terra","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes: Results from the CANVAS Program Randomised Clinical Trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and Safety of Empagliflozin Added to Existing Antidiabetes Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of Ertugliflozin on Heart Failure\u2013Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"ref_24","first-page":"100294","article-title":"Unlocking the Secrets to Human NTCP Structure","volume":"3","author":"Qi","year":"2022","journal-title":"Innovation"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhou, J., and Li, T. (2022). Regulation of the HBV Entry Receptor NTCP and Its Potential in Hepatitis B Treatment. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.879817"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sagnelli, C., Sagnelli, E., Russo, A., Pisaturo, M., Occhiello, L., and Coppola, N. (2021). HBV\/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. Life, 11.","DOI":"10.3390\/life11020169"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1194\/jlr.R049437","article-title":"Key Discoveries in Bile Acid Chemistry and Biology and Their Clinical Applications: History of the Last Eight Decades","volume":"55","author":"Hofmann","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/liv.14553","article-title":"Potential of Ileal Bile Acid Transporter Inhibition as a Therapeutic Target in Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis","volume":"40","author":"Kamath","year":"2020","journal-title":"Liver Int."},{"key":"ref_29","first-page":"G157","article-title":"Expression and Transport Properties of the Human Ileal and Renal Sodium-Dependent Bile Acid Transporter","volume":"274","author":"Craddock","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/mp060022d","article-title":"Apical Sodium Dependent Bile Acid Transporter (ASBT, SLC10A2): A Potential Prodrug Target","volume":"3","author":"Balakrishnan","year":"2006","journal-title":"Mol. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cld.2018.06.001","article-title":"Alagille Syndrome","volume":"22","author":"Mitchell","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7470","DOI":"10.3748\/wjg.v26.i47.7470","article-title":"Molecular Overview of Progressive Familial Intrahepatic Cholestasis","volume":"26","author":"Amirneni","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_33","unstructured":"Scheffel, A.R. (1952). Use of Benemid in Enhancement of Serum Blood Levels of Pencillin. [Ph.D. Thesis, University of Nebraska Medical Center]."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.mam.2012.10.010","article-title":"The SLC22 Family with Transporters of Organic Cations, Anions and Zwitterions","volume":"34","author":"Koepsell","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0006-291X(02)02853-X","article-title":"Organic Anion and Cation Transporters Occur in Pairs of Similar and Similarly Expressed Genes","volume":"300","author":"Eraly","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/dmd.107.014902","article-title":"Expression of Thirty-Six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines","volume":"35","author":"Hilgendorf","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1254\/jphs.93.430","article-title":"Expression of Human Organic Anion Transporters in the Choroid Plexus and Their Interactions with Neurotransmitter Metabolites","volume":"93","author":"Alebouyeh","year":"2003","journal-title":"J. Pharmacol. Sci."},{"key":"ref_38","first-page":"279","article-title":"Benemid (p-Di-n-Propylsulfamyl)-Benzoic Acid) as Uricosuric Agent in Chronic Gouty Arthritis","volume":"64","author":"Gutman","year":"1951","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8","article-title":"Gout: Six-Year Follow-up on Probenecid (Benemid) Therapy","volume":"2","author":"Bartels","year":"1959","journal-title":"Arthritis Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular Identification of a Renal Urate Anion Exchanger That Regulates Blood Urate Levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/00498250600861751","article-title":"Expression Profiles of 50 Xenobiotic Transporter Genes in Humans and Pre-Clinical Species: A Resource for Investigations into Drug Disposition","volume":"36","author":"Bleasby","year":"2006","journal-title":"Xenobiotica"},{"key":"ref_42","unstructured":"EMA Summary of Product Characteristics (2024, February 27). ZURAMPIC, INN-Lesinurad 2017. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zurampic-epar-product-information_en.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout. Was Its Withdrawal from the Market in the Best Interest of Patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf."},{"key":"ref_44","first-page":"84","article-title":"Analysis of Uric Acid Transport in Renal Tubules Using Benzbromarone and Pyrazinamide","volume":"28","author":"Moriwaki","year":"1990","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"ref_45","unstructured":"(2024, February 27). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process."},{"key":"ref_46","unstructured":"(2024, February 27). BfArM-Arzneimittel Recherchieren. Available online: https:\/\/www.bfarm.de\/DE\/Arzneimittel\/Arzneimittelinformationen\/Arzneimittel-recherchieren\/_node.html."},{"key":"ref_47","unstructured":"(2024, February 27). SAI-Detailed View. Available online: https:\/\/sai.refdata.ch\/detail\/37885."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of Human Sodium Glucose Transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-Mediated Transport Explains Renal Glucose Reabsorption during Genetic and Pharmacological SGLT2 Inhibition in Euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide Trends in Diabetes since 1980: A Pooled Analysis of 751 Population-Based Studies with 4.4 Million Participants","volume":"387","author":"Zhou","year":"2016","journal-title":"Lancet"},{"key":"ref_52","unstructured":"Lifton, R.P., Somlo, S., Giebisch, G.H., and Seldin, D.W. (2009). Diseases of Renal Glucose Handling. Genetic Diseases of the Kidney, Academic Press."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/dc09-0749","article-title":"Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms: The Kelly West Award Lecture 2008","volume":"33","author":"Laakso","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1172\/JCI10963","article-title":"Ornithine Decarboxylase, Kidney Size, and the Tubular Hypothesis of Glomerular Hyperfiltration in Experimental Diabetes","volume":"107","author":"Thomson","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","article-title":"Knockout of Na-Glucose Transporter SGLT2 Attenuates Hyperglycemia and Glomerular Hyperfiltration but Not Kidney Growth or Injury in Diabetes Mellitus","volume":"304","author":"Vallon","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 Inhibitor Empagliflozin Reduces Renal Growth and Albuminuria in Proportion to Hyperglycemia and Prevents Glomerular Hyperfiltration in Diabetic Akita Mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1074\/jbc.C117.794982","article-title":"A Dual Agonist of Farnesoid X Receptor (FXR) and the G Protein\u2013Coupled Receptor TGR5, INT-767, Reverses Age-Related Kidney Disease in Mice","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2337\/dc14-0920","article-title":"Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People with Type 1 and Type 2 Diabetes: A Cohort Study","volume":"38","author":"Khunti","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting Renal Glucose Reabsorption to Treat Hyperglycaemia: The Pleiotropic Effects of SGLT2 Inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a Novel Selective Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor: Characterisation and Comparison with Other SGLT-2 Inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Choi, C.-I. (2016). Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents. Molecules, 21.","DOI":"10.3390\/molecules21091136"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/ki.2010.511","article-title":"SGLT2 Inhibitors: Molecular Design and Potential Differences in Effect","volume":"79","author":"Isaji","year":"2011","journal-title":"Kidney Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular Hyperfiltration in Experimental Diabetes Mellitus: Potential Role of Tubular Reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and Chronic Effects of SGLT2 Blockade on Glomerular and Tubular Function in the Early Diabetic Rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a Novel Inhibitor of Sodium Glucose Co-transporter 2, Dose Dependently Reduces Calculated Renal Threshold for Glucose Excretion and Increases Urinary Glucose Excretion in Healthy Subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following 4 Weeks\u2019 Treatment with Empagliflozin Once Daily in Patients with Type 2 Diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na+-d-Glucose Cotransporter SGLT1 Is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion","volume":"61","author":"Gorboulev","year":"2011","journal-title":"Diabetes"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","article-title":"Improved Glycemic Control in Mice Lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_73","unstructured":"EMA Summary of Product Characteristics (2024, March 06). FORXIGA, INN-Canagliflozin 2020. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/forxiga-epar-product-information_en.pdf."},{"key":"ref_74","unstructured":"(2024, March 06). Forxiga|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/forxiga."},{"key":"ref_75","unstructured":"(2024, March 06). Edistride|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/edistride."},{"key":"ref_76","unstructured":"(2024, March 06). FDA Medication Guide Farxiga 2020, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202293s020lbl.pdf."},{"key":"ref_77","unstructured":"(2024, March 07). Dapagliflozin Viatris|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dapagliflozin-viatris."},{"key":"ref_78","unstructured":"(2024, March 07). Ebymect|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ebymect."},{"key":"ref_79","unstructured":"(2024, March 07). Xigduo|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xigduo."},{"key":"ref_80","unstructured":"(2024, March 07). Qtern|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qtern."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/dme.12624","article-title":"Efficacy and Safety of Dapagliflozin Monotherapy in People with Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled 102-Week Trial","volume":"32","author":"Bailey","year":"2015","journal-title":"Diabet. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus Glipizide as Add-on Therapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Metformin: A Randomized, 52-Week, Double-Blind, Active-Controlled Noninferiority Trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin with or without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/dc14-0666","article-title":"Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial","volume":"38","author":"Matthaei","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-Term Efficacy of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Receiving High Doses of Insulin","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide Once Weekly plus Dapagliflozin Once Daily versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy (DURATION-8): A 28 Week, Multicentre, Double-Blind, Phase 3, Randomised Controlled Trial","volume":"4","author":"Guja","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a Randomized, Placebo-Controlled Study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_89","unstructured":"EMA Summary of Product Characteristics (2024, March 08). INVOKANA, INN-Canagliflozin 2023. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/invokana-epar-product-information_en.pdf."},{"key":"ref_90","unstructured":"(2024, March 08). FDA Medication Guide Invokana 2017, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/204042s026lbl.pdf."},{"key":"ref_91","unstructured":"(2024, March 08). Vokanamet|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vokanamet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13300-015-0117-z","article-title":"Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial","volume":"6","author":"Fulcher","year":"2015","journal-title":"Diabetes Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium\u2013Glucose Cotransporter 2, When Used in Conjunction with Insulin Therapy in Patients with Type 2 Diabetes","volume":"38","author":"Neal","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.12684","article-title":"Efficacy and Safety of Titrated Canagliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Sulphonylurea: A Randomised Trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and Safety of Canagliflozin over 52 Weeks in Patients with Type 2 Diabetes on Background Metformin and Pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and Safety of Canagliflozin versus Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled with Metformin (CANTATA-SU): 52 Week Results from a Randomised, Double-Blind, Phase 3 Non-Inferiority Trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin Compared with Sitagliptin for Patients with Type 2 Diabetes Who Do Not Have Adequate Glycemic Control with Metformin Plus Sulfonylurea: A 52-Week Randomized Trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_100","unstructured":"EMA Summary of Product Characteristics (2024, March 08). JARDIANCE, INN-Empagliflozin 2024. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jardiance-epar-product-information_en.pdf."},{"key":"ref_101","unstructured":"(2024, March 08). FDA Medication Guide Jardiance 2022, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204629s033lbl.pdf."},{"key":"ref_102","unstructured":"(2024, March 08). Glyxambi|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glyxambi."},{"key":"ref_103","unstructured":"(2024, March 08). Synjardy|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/synjardy."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Merker","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_105","first-page":"171","article-title":"Glyxambi (Empagliflozin\/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2213-8587(22)00387-4","article-title":"Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin versus Placebo and the DPP-4 Inhibitor Linagliptin versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial","volume":"11","author":"Laffel","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2337\/dc14-2365","article-title":"Initial Combination of Empagliflozin and Linagliptin in Subjects with Type 2 Diabetes","volume":"38","author":"Lewin","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of Empagliflozin and Glimepiride as Add-on to Metformin in Patients with Type 2 Diabetes: A 104-Week Randomised, Active-Controlled, Double-Blind, Phase 3 Trial","volume":"2","author":"Andersen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dc16-0522","article-title":"Initial Combination of Empagliflozin and Metformin in Patients with Type 2 Diabetes","volume":"39","author":"Hadjadj","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of Empagliflozin Added on to Basal Insulin in Type 2 Diabetes Inadequately Controlled on Basal Insulin: A 78-Week Randomized, Double-Blind, Placebo-Controlled Trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved Glucose Control with Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia with Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_112","unstructured":"EMA Summary of Product Characteristics (2024, March 08). STEGLATRO, INN-Ertugliflozin 2018. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/steglatro-epar-product-information_en.pdf."},{"key":"ref_113","unstructured":"(2024, March 08). FDA Medication Guide Steglatro 2017, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209803s000lbl.pdf."},{"key":"ref_114","unstructured":"(2024, March 08). Segluromet|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/segluromet."},{"key":"ref_115","unstructured":"(2024, March 08). Steglujan|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/steglujan."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-018-0878-6","article-title":"Ertugliflozin: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/dom.13251","article-title":"Long-Term Efficacy and Safety of Ertugliflozin Monotherapy in Patients with Inadequately Controlled T2DM despite Diet and Exercise: VERTIS MONO Extension Study","volume":"20","author":"Aronson","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of Ertugliflozin on Glucose Control, Body Weight, Blood Pressure and Bone Density in Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13300-017-0354-4","article-title":"Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study","volume":"9","author":"Hollander","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.13194","article-title":"Ertugliflozin plus Sitagliptin versus Either Individual Agent over 52 Weeks in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin: The VERTIS FACTORIAL Randomized Trial","volume":"20","author":"Pratley","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13300-017-0358-0","article-title":"Ertugliflozin and Sitagliptin Co-Initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study","volume":"9","author":"Miller","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.13116","article-title":"Efficacy and Safety of the Addition of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Sitagliptin: The VERTIS SITA2 Placebo-controlled Randomized Study","volume":"20","author":"Liu","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_123","unstructured":"(2024, March 07). FDA Medication Guide Inpefa 2023, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216203s000lbl.pdf."},{"key":"ref_124","unstructured":"(2024, March 07). Zynquista|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zynquista."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41586-022-04845-4","article-title":"Structure of the Bile Acid Transporter and HBV Receptor NTCP","volume":"606","author":"Asami","year":"2022","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41422-022-00680-4","article-title":"Structure of Human NTCP Reveals the Basis of Recognition and Sodium-Driven Transport of Bile Salts into the Liver","volume":"32","author":"Liu","year":"2022","journal-title":"Cell Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/jvh.13490","article-title":"Clinical Effects of NTCP-Inhibitor Myrcludex B","volume":"28","author":"Cheng","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final Results of a Multicenter, Open-Label Phase 2b Clinical Trial to Assess Safety and Efficacy of Myrcludex B in Combination with Tenofovir in Patients with Chronic HBV\/HDV Co-Infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jvh.13081","article-title":"New Treatment Options for Delta Virus: Is a Cure in Sight?","volume":"26","author":"Yurdaydin","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"GS-13-Final Results of a Multicenter, Open-Label Phase 2 Clinical Trial (MYR203) to Assess Safety and Efficacy of Myrcludex B in Cwith PEG-Interferon Alpha 2a in Patients with Chronic HBV\/HDV Co-Infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile Acid Transporters","volume":"50","author":"Dawson","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep4.1468","article-title":"Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study","volume":"22","author":"Kamath","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"S626","DOI":"10.1016\/S0168-8278(18)31509-5","article-title":"The Natural Course of FIC1 Deficiency and BSEP Deficiency: Initial Results from the NAPPED-Consortium (Natural Course and Prognosis of PFIC and Effect of Biliary Diversion)","volume":"68","author":"Wessel","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_135","first-page":"75","article-title":"Cholestatic Pruritus: An Update","volume":"82","author":"Nevens","year":"2019","journal-title":"Acta Gastroenterol. Belg."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinre.2010.10.007","article-title":"Pathophysiology and Current Management of Pruritus in Liver Disease","volume":"35","author":"Kremer","year":"2011","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and Safety of Maralixibat Treatment in Patients with Alagille Syndrome and Cholestatic Pruritus (ICONIC): A Randomised Phase 2 Study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s40265-021-01594-y","article-title":"Odevixibat: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat Treatment in Progressive Familial Intrahepatic Cholestasis: A Randomised, Placebo-Controlled, Phase 3 Trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"100782","DOI":"10.1016\/j.jhepr.2023.100782","article-title":"Interim Results from an Ongoing, Open-Label, Single-Arm Trial of Odevixibat in Progressive Familial Intrahepatic Cholestasis","volume":"5","author":"Thompson","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_141","unstructured":"Thompson, R.J., Horn, P., Houwen, R.H.J., Lacaille, F., Ni, Q., Stein, P., Tessier, M.E., Thompson, C., Vittorio, J.M., and Kjems, L. (2021, January 23). Substantial Clinical Benefits with Odevixibat Treatment across Progressive Familial Intrahepatic Cholestasis Genetic Deficiencies: Subgroup Analysis of Serum Bile Acids, Pruritus, and Safety Using Pooled Data from the PEDFIC 1 and 2 Studies. Proceedings of the International Liver Congress, online."},{"key":"ref_142","first-page":"258","article-title":"Benemid: An Anticatabolite; Its Pharmacological Properties","volume":"9","author":"Beyer","year":"1950","journal-title":"Fed. Proc."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003088-198106020-00004","article-title":"Clinical Pharmacokinetics of Probenecid","volume":"6","author":"Cunningham","year":"1981","journal-title":"Clin. Pharmacokinet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.2600711114","article-title":"Pharmacokinetics of Probenecid Following Oral Doses to Human Volunteers","volume":"71","author":"Selen","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"ref_145","first-page":"276","article-title":"Benemid and Carinamide: Comparison of Effect on Para-Aminosalicylic Acid (PAS) Plasma Concentrations","volume":"36","author":"Boger","year":"1950","journal-title":"J. Lab. Clin. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","article-title":"The History and Future of Probenecid","volume":"12","author":"Robbins","year":"2012","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/jac\/dkac200","article-title":"Addition of Probenecid to Oral \u03b2-Lactam Antibiotics: A Systematic Review and Meta-Analysis","volume":"77","author":"Wilson","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/17425255.2.4.505","article-title":"Drug-Drug Interactions Involving Membrane Transporters in the Human Kidney","volume":"2","author":"Li","year":"2006","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1757-1146-4-13","article-title":"Revisiting the Pathogenesis of Podagra: Why Does Gout Target the Foot?","volume":"4","author":"Roddy","year":"2011","journal-title":"J. Foot Ankle Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1759720X221114098","DOI":"10.1177\/1759720X221114098","article-title":"A Glance into the Future of Gout","volume":"14","author":"Sivera","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3899\/jrheum.121301","article-title":"Efficacy and Tolerability of Probenecid as Urate-Lowering Therapy in Gout; Clinical Experience in High-Prevalence Population","volume":"40","author":"Pui","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular Risks of Probenecid versus Allopurinol in Older Patients with Gout","volume":"71","author":"Kim","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11926-996-0044-0","article-title":"Renal Urate Handling: Clinical Relevance of Recent Advances","volume":"7","author":"Anzai","year":"2005","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of Allopurinol and Benzbromarone for the Control of Hyperuricaemia. A Pathogenic Approach to the Treatment of Primary Chronic Gout","volume":"57","author":"Calabozo","year":"1998","journal-title":"Ann. Rheum. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A Randomised Controlled Trial on the Efficacy and Tolerability with Dose Escalation of Allopurinol 300\u2013600 Mg\/Day versus Benzbromarone 100\u2013200 Mg\/Day in Patients with Gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of Urate-Lowering Therapy on the Velocity of Size Reduction of Tophi in Chronic Gout","volume":"47","author":"Calabozo","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_157","first-page":"1620","article-title":"Comparative Effectiveness of Allopurinol, Febuxostat and Benzbromarone on Renal Function in Chronic Kidney Disease Patients with Hyperuricemia: A 13-Year Inception Cohort Study","volume":"33","author":"Chou","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Yang, N., Dong, Y.-Q., Jia, G.-X., Fan, S.-M., Li, S.-Z., Yang, S.-S., and Li, Y.-B. (2020). ASBT(SLC10A2): A Promising Target for Treatment of Diseases and Drug Discovery. Biomed. Pharmacother., 132.","DOI":"10.1016\/j.biopha.2020.110835"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Carmichael, N., and Day, P.J.R. (2022). Cell Surface Transporters and Novel Drug Developments. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.852938"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/6926\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:03:52Z","timestamp":1760108632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/6926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":159,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25136926"],"URL":"https:\/\/doi.org\/10.3390\/ijms25136926","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}